Meta-tyrosine. A powerful anti-metastatic factor with undetectable toxic-side effects.

Abstract

Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. While former studies have indicated that T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifestation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. In this work, we have extended our previous findings demonstrating that a periodic intravenous administration of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two different metastatic murine tumors and decreased the rate of death from 100% up to 25% in tumor-excised mice that already exhibited established metastases at the time of surgery. These anti-metastatic effects were achieved even at very low concentrations and without displaying any detectable toxic-side effects, suggesting that the use of meta-tyrosine may help to develop new and less harmful means of managing malignant diseases, especially those aimed to control the growth of metastases that is the most serious problem in cancer pathology.

• Authors: Damián Machuca, Paula Chiarella, Daniela Montagna, Graciela Dran, Roberto P Meiss, Raúl A Ruggiero
• Journal: Medicina (Medicina (B Aires)) Vol. 75 Issue 1 Pg. 1-5 ( 2015) ISSN: 0025-7680 [Print] Argentina
• PMID: 25637892 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Tyrosine
• 3-tyrosine

Topics

• Animals
• Antineoplastic Agents (administration & dosage, blood, chemistry)
• Carcinoma (pathology, prevention & control)
• Dose-Response Relationship, Drug
• Isomerism
• Liver Neoplasms (prevention & control, secondary)
• Lung Neoplasms (prevention & control, secondary)
• Mammary Neoplasms, Experimental (pathology)
• Mice, Inbred BALB C
• Tyrosine (administration & dosage, adverse effects, chemistry)